Form 4: Inhibrx Biosciences Director Jon Faiz Kayyem Reports Gift of Shares

Director Jon Faiz Kayyem reports a gift of 90,000 shares of Inhibrx Biosciences common stock and disclaims beneficial ownership of shares held in various trusts and custodial accounts.

Summary

• On March 27, 2025, Jon Faiz Kayyem, a director of Inhibrx Biosciences, reported a transaction involving the gift of 90,000 shares of common stock.
• The shares were gifted from The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the reporting person's adult children not residing in the reporting person's household.
• Kayyem also disclaims beneficial ownership of shares held in The Jon Faiz Kayyem and Paige Gates-Kayyem Family Trust (419,360 shares), the Jon Faiz Kayyem Revocable Trust (250,000 shares), the Paige Gates-Kayyem Revocable Trust (250,000 shares), and custodial accounts for Child A and Child B (69,843 shares each).

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a gift of shares and disclaimers of beneficial ownership. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the ownership structure of Inhibrx Biosciences.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The information disclosed is consistent with SEC regulations regarding insider trading and beneficial ownership reporting.
• Similar filings can be observed for directors and officers of comparable biotechnology companies such as Amgen, Regeneron, and Gilead Sciences.

Stakeholder Impact

• The gift of shares may have a minor impact on the overall shareholder base.
• The disclaimers of beneficial ownership clarify the ownership structure for investors.

Key Dates

Keywords

Form 4, beneficial ownership, director, Inhibrx Biosciences, INBX, Kayyem, shares, gift, trust, custodial account